Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Urs Heilbronner

Showing results (51-60 of 116) with videos related to

Pageof 12
Sort By:
Pharmaceuticals (Basel, Switzerland)|February 24, 2024
A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical StudyTeuntje A D Pelgrim, Alexandra Philipsen, Allan H Young, et al.
Translational Psychiatry|November 9, 2022
Comparative serum proteomic analysis of a selected protein panel in individuals with schizophrenia and bipolar disorder and the impact of genetic risk burden on serum proteomic profilesMojtaba Oraki Kohshour, Nirmal R Kannaiyan, August Jernbom Falk, et al.
Psychoneuroendocrinology|April 24, 2026
Investigating the association of a selected inflammatory protein panel with suicide attempts in the PsyCourse Study: A pilot studyMojtaba Oraki Kohshour, Monika Budde, Pierre Solomon, et al.
Translational Psychiatry|March 29, 2025
Investigating the association of the plasma lipidomic profile with cognitive performance and genetic risk in the PsyCourse studyMojtaba Oraki Kohshour, Sergi Papiol, Anna Tkachev, et al.
The EMBO Journal|March 26, 2024
Regulation of Zbp1 by miR-99b-5p in microglia controls the development of schizophrenia-like symptoms in miceLalit Kaurani, Md Rezaul Islam, Urs Heilbronner, et al.
Schizophrenia Research|January 18, 2023
Genetic contributions to transdiagnostic symptom dimensions in patients with major depressive disorder, bipolar disorder, and schizophrenia spectrum disordersFriederike S David, Frederike Stein, Till F M Andlauer, et al.
Psychiatry Research|April 16, 2025
How variants in inflammatory mediator genes influence symptom severity of psychiatric disorders: Findings from the PsyCourse studyMojtaba Oraki Kohshour, Kristina Adorjan, Monika Budde, et al.
Scientific Reports|March 17, 2026
Polygenic scores for executive functioning as predictors of performance improvements after repeated testing in major psychiatric disordersAlba Navarro-Flores, Maria Heilbronner, Hajar Rafiee, et al.
Translational Psychiatry|March 25, 2023
Medication adherence and cognitive performance in schizophrenia-spectrum and bipolar disorder: results from the PsyCourse StudyFanny Senner, Lena Hiendl, Susanne Bengesser, et al.
European Archives of Psychiatry and Clinical Neuroscience|July 4, 2026
Effects of quetiapine on cognitive functioning in schizophrenia: evidence for the remyelination hypothesis?Marcus Ising, Florian Raabe, Laura Fischer, et al.
Pageof 12

Showing results (51-60 of 116) with videos related to

Sort By:
Pageof 12
Pharmaceuticals (Basel, Switzerland)|February 24, 2024
A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical StudyTeuntje A D Pelgrim, Alexandra Philipsen, Allan H Young, et al.
Translational Psychiatry|November 9, 2022
Comparative serum proteomic analysis of a selected protein panel in individuals with schizophrenia and bipolar disorder and the impact of genetic risk burden on serum proteomic profilesMojtaba Oraki Kohshour, Nirmal R Kannaiyan, August Jernbom Falk, et al.
Psychoneuroendocrinology|April 24, 2026
Investigating the association of a selected inflammatory protein panel with suicide attempts in the PsyCourse Study: A pilot studyMojtaba Oraki Kohshour, Monika Budde, Pierre Solomon, et al.
Translational Psychiatry|March 29, 2025
Investigating the association of the plasma lipidomic profile with cognitive performance and genetic risk in the PsyCourse studyMojtaba Oraki Kohshour, Sergi Papiol, Anna Tkachev, et al.
The EMBO Journal|March 26, 2024
Regulation of Zbp1 by miR-99b-5p in microglia controls the development of schizophrenia-like symptoms in miceLalit Kaurani, Md Rezaul Islam, Urs Heilbronner, et al.
Schizophrenia Research|January 18, 2023
Genetic contributions to transdiagnostic symptom dimensions in patients with major depressive disorder, bipolar disorder, and schizophrenia spectrum disordersFriederike S David, Frederike Stein, Till F M Andlauer, et al.
Psychiatry Research|April 16, 2025
How variants in inflammatory mediator genes influence symptom severity of psychiatric disorders: Findings from the PsyCourse studyMojtaba Oraki Kohshour, Kristina Adorjan, Monika Budde, et al.
Scientific Reports|March 17, 2026
Polygenic scores for executive functioning as predictors of performance improvements after repeated testing in major psychiatric disordersAlba Navarro-Flores, Maria Heilbronner, Hajar Rafiee, et al.
Translational Psychiatry|March 25, 2023
Medication adherence and cognitive performance in schizophrenia-spectrum and bipolar disorder: results from the PsyCourse StudyFanny Senner, Lena Hiendl, Susanne Bengesser, et al.
European Archives of Psychiatry and Clinical Neuroscience|July 4, 2026
Effects of quetiapine on cognitive functioning in schizophrenia: evidence for the remyelination hypothesis?Marcus Ising, Florian Raabe, Laura Fischer, et al.
Pageof 12